Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-JMJ-129
- Development stage
- Phase 1
- Lead developer
- National Institute of Mental Health
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
11C-JMJ-129 is a novel radiotracer developed for positron emission tomography (PET) imaging of phosphodiesterase-4D (PDE4D) in the brain. It is a carbon-11 labeled small molecule designed to selectively bind to PDE4D, an enzyme implicated in cognitive function and neuropsychiatric disorders. The compound demonstrates high specificity and affinity for PDE4D with minimal off-target binding, as confirmed by extensive receptor screening. In preclinical studies using non-human primates, 11C-JMJ-129 showed robust brain uptake and excellent signal stability, with selective binding that could be blocked by known PDE4D inhibitors such as BPN14770 or rolipram. Its metabolic profile indicates high stability in brain tissue and favorable characteristics for PET imaging applications[1][3][5]. The primary intended use of 11C-JMJ-129 is as a diagnostic agent to visualize and quantify PDE4D distribution in vivo during PET scans[7].
- Other names
- [11C]JMJ-129
02
Targets
PDE4D (Phosphodiesterase 4D)
Beyond the preview
Go deeper on 11C-JMJ-129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C-JMJ-129.